<qa>  What is the primary objective of the study?The present study will examine the effects of liraglutide treatment during 26 weeks on several cardiovascular risk factors in patients with prediabetes and end-stage renal disease ESRD. The primary objective is to determine the efficacy of the treatment on glucose tolerance evaluated during a 3h 75g-oral glucose tolerance test OGTT. Secondary objectives include various clinical and biochemical cardiovascular and safety parameters. 